Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation - Full Text View

Purpose

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings

Condition	Intervention	Phase
Parkinson's Disease Essential Tremor Dystonia	Drug: Dexmedetomidine Hydrochloride Infusion Drug: Normal Saline	Phase II Phase III

Genetics Home Reference related topics:

early-onset primary dystonia essential tremor familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics:

Dystonia Parkinson's Disease Tremor

Drug Information available for:

Sodium chloride Dexmedetomidine Dexmedetomidine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:

Micro-electrode Recordings [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Neurological Exam Findings [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Estimated Enrollment:	90
Study Start Date:	January 2008
Estimated Study Completion Date:	January 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
PD-STN: Experimental Parkinson's Disease -- STN target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
PD - GPi: Experimental Parkinson's Disease -- GPi target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
ET - VIM: Experimental Essential Tremor -- VIM target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
Dystonia - GPi: Experimental Dystonia -- GPi target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
PD - STN Control: Placebo Comparator Parkinson's Disease -- STN target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
PD - GPi Control: Placebo Comparator Parkinson's Disease -- GPi target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
ET - VIM Control: Placebo Comparator Essential Tremor -- VIM target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Dystonia - GPi Control: Placebo Comparator Dystonia -- GPi target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Detailed Description:

Deep brain stimulator (DBS) implants are used in the treatment of medically refractory movement disorders such as Parkinson's disease, essential tremor and dystonia. Because of the uniqueness of each individual brain, the surgery to implant a DBS electrode requires detailed anatomic and physiological information for each patient. The anatomic data is obtained before surgery via a Magnetic Resonance Imaging (MRI) scan of the patient's brain. Physiological data is obtained during the operation via micro-electrode recording of the patient's brain and neurological examination of the patient. Therefore, DBS surgery can be uncomfortable to patients, as it can be very time consuming and requires the patient to be awake and attentive.

The specific aims of this project are:

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings.
To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery have no significant effects on neurological findings and/or patient cooperation during neurological examination.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Any patient who has agreed to undergo DBS implantation.

Exclusion Criteria:

Patients who fail recommendation for DBS surgery discussed in Vanderbilt University Movement Disorder Clinical Conference.
Patients not consented for DBS surgery.
Patients or legal guardians not able to provide informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608231

Contacts


Contact: Joseph Neimat, M.D.	615-322-7417	joseph.neimat@Vanderbilt.Edu

Contact: Melba T. Isom	615-343-9822	melba.isom@vanderbilt.edu

Locations


United States, Tennessee
	Vanderbilt University Medical Center	Recruiting
	Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

Vanderbilt University

Investigators


Principal Investigator:	Joseph Neimat, M.D.	Vanderbilt University

More Information

Responsible Party:	Vanderbilt University ( Joseph Neimat, M.D. )
Study ID Numbers:	070666
First Received:	January 7, 2008
Last Updated:	January 25, 2008
ClinicalTrials.gov Identifier:	NCT00608231
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Dystonic Disorders

Essential Tremor

Ganglion Cysts

Basal Ganglia Diseases

Dystonia

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Tremor

Dyskinesias

Signs and Symptoms

Movement Disorders

Parkinson Disease

Benign essential tremor syndrome

Neurologic Manifestations

Dexmedetomidine

Parkinsonian Disorders

Additional relevant MeSH terms:

Neurotransmitter Agents

Adrenergic alpha-Agonists

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Nervous System Diseases

Physiological Effects of Drugs

Central Nervous System Depressants

Pharmacologic Actions

Adrenergic Agonists

Analgesics, Non-Narcotic

Sensory System Agents

Therapeutic Uses

Hypnotics and Sedatives

Analgesics

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on November 03, 2008

Sponsored by:	Vanderbilt University
Information provided by:	Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00608231